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Rationale
RPL554 is a novel dual phosphodiesterase (PDE) 3 and 4
isoenzymes inhibitor that has been demonstrated to
have both potent, long-acting bronchodilator and anti-
inflammatory activity in preclinical models.
Objectives
To evaluate the safety, bronchodilator and bronchopro-
tective effects of single ascending doses of RPL554 in
healthy subjects and asthmatics.
Methods
The safety of RPL554 0.003 and 0.009 mg/kg was evalu-
ated in 18 healthy males (age 18-41 years; weight 58-90
kg; height 168-196 cm; BMI 18-29 kg/m2) in a rando-
mised, double-blind study. For each dose group, 6 subjects
inhaled RPL554 and 3 placebo. Study medication was
administered by a calibrated electronic nebuliser and oro-
nasal mask. Subsequently, RPL554 0.009 and 0.018 mg/kg
were evaluated in 6 asthmatic males (22-29 years; 58-98
kg; 174-198 cm; BMI 19-27 kg/m2, FEV1 75-118% pred.)
using an open, adaptive design to select an effective dose.
This dose (0.018 mg/kg) was further evaluated in a rando-
mised, double-blind, placebo-controlled, cross-over study
in 10 allergic asthmatics (20-50 years; 67-112 kg; 171-191
cm; BMI 21-33 kg/m2, FEV1 82-112% pred.; baseline
PC20(methacholine=MCh) 0.07-1.49 mg/ml; not on con-
troller medication) to assess its bronchodilator effects and
bronchoprotective activity against methacholine (MCh)
challenge.
Results
Inhaled RPL554 0.003 to 0.018 mg/kg was well-tolerated
in all subjects studied. In the asthmatics, RPL554 0.018
mg/kg produced a rapidly progressive, sustained broncho-
dilation with a mean maximal increase in FEV1 of 520 ml
(95% CI: 320-720 ml; p=0.0061), or 15% increase from
baseline. Furthermore, a single dose of RPL554 increased
PC20 (MCh) by a mean of 1.46 doubling doses (95% CI:
0.63 – 2.28; p=0.004) versus placebo. Adverse events were
mild, transient and generally of equal frequency in RPL554
and placebo treated groups. No significant changes in
heart rate or systemic blood pressure were noted with
RPL554 when compared to placebo.
Conclusions
RPL554 was well-tolerated in the healthy subjects and
asthmatics studied. In patients with mild asthma, a rapid,
potent and long-lasting bronchodilator response was pro-
duced. The maximum bronchodilator effect appeared at
least comparable to published values of inhaled salbuta-
mol. RPL554 has the potential to become a first-in-class
bronchodilator for airways obstruction.
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